- ￥389 - 2940
- AmBeed
- A1550219
- 2026年05月28日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 英文名：
(10-(1-(2,4-Dichlorobenzyl)-1H-indazole-3-carboxamido)decyl)triphenylphosphonium bromide
- 供应商：
上海安毕达生物科技有限公司
- CAS号：
2361564-49-8
- 规格：
50μL/1mL/1mg/5mg/10mg
| 规格： | 50μL | 产品价格： | ￥389.0 |
|---|---|---|---|
| 规格： | 1mL | 产品价格： | ￥2592.0 |
| 规格： | 1mg | 产品价格： | ￥840.0 |
| 规格： | 5mg | 产品价格： | ￥2205.0 |
| 规格： | 10mg | 产品价格： | ￥2940.0 |
Mito-LND (Mito-Lonidamine) is an orally administered, mitochondria-focused inhibitor of oxidative phosphorylation (OXPHOS). It disrupts mitochondrial bioenergetics, promotes the production of reactive oxygen species, and triggers autophagic cell death in lung cancer cells1.
Mito-LND impedes the growth, migration, and invasion of lung cancer. It effectively inhibits the proliferation of H2030BrM3 and A549 cells, demonstrating IC50 values of 0.74 µM and 0.69 µM, respectively1.
Mito-LND suppresses the activities of mitochondrial complex I and II in H2030BrM3 cells, exhibiting IC50 values of 1.2 µM and 2.4 µM, respectively1.
Mito-LND (1 µM) enhances ROS production in H2030BrM3 lung cancer cells. It effectively stimulates mitochondrial ROS generation in these cells1.
Mito-LND (2 µM) reduces phosphorylated AKT levels and decreases the phosphorylation of P70S6K and other energy-sensing proteins in both parental and metastatic lung cancer cell lines, specifically targeting mTOR signaling downregulation1.
Mito-LND treatment (7.5 µmol/kg; oral gavage; 5 days per week; for 3 consecutive weeks) significantly increased efficacy in combating both lung cancer progression and metastasis1.
Mito-LND also reduces the growth rate of A549 tumor xenografts1.
Mito-LND treatment significantly reduces brain metastasis of lung cancer in NOD/SCID mice implanted with H2030BrM3 cells1.
Mito-LND treatment (7.5 µmol/kg; oral gavage; 5 days per week; for 3 consecutive weeks) significantly increased efficacy in combating both lung cancer progression and metastasis1.
Mito-LND also reduces the growth rate of A549 tumor xenografts1.
Mito-LND treatment significantly reduces brain metastasis of lung cancer in NOD/SCID mice implanted with H2030BrM3 cells1.
溶解方案(细胞实验)
DMSO 中的溶解度 : 50 mg/mL (62.37 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)
溶解方案(动物实验)
"方案 一": "请依序添加每种溶剂：10% DMSO 40% PEG300 5% Tween-80 45% SalineSolubility: ≥ 2.5 mg/mL (3.12 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。"
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Animal Models for Lesch-Nyhan Disease
behavior (SMB) involving intense biting of the digits and lips. Careful metabolic study showed profound hyperuricemia and hyperuricosuria in this syndrome, now known as Lesch-Nyhan disease (LND). When adjusted for body wt, total daily UA excretion
Cell：清华俞立团队首次发现迁移体介导的线粒体胞吐，一种新型线粒体质控过程
。图片来源：Cell在中性粒细胞中，该研究首先判断了中性粒细胞产生的迁移体是否含有线粒体。将中性粒细胞分离出来用 Mito-SOX 染色来标记受损的线粒体，然后将这些中性粒细胞注射回小鼠体内，发现确实有许多中性粒细胞产生的迁移体含有 Mito-SOX 信号。其次，通过对血液中分离出迁移体进行鉴定发现大约 87% 的迁移体来自中性粒细胞。通过 TEM 观察发现分离出的迁移体高度均一，并具有迁移体的形态特征，而且许多孤立的迁移体都含有受损的线粒体，这就证明了线粒体胞吐同样能够在体内发生。图片来源
1. embryos are dissected from timed-pregnant mice from 10.5-11.5 d.p.c. 2. limb buds are microdissected and placed in holding medium (L15 medium supplemented with 1 x MITO+ serum extender) (all media is supplemented with 100 U penicillin/ml
技术资料暂无技术资料 索取技术资料
